Roche RxDx Collaboration in Oncology: Achievements in Drug/CDx Co-Development
Time: 2:35 pm
day: Day 1 - Track B (1)
Details:
- Roche RxDx partnerships are the cornerstone of our R&D strategy
- Roche and Foundation Medicine (FMI) collaborate on drug and CDx co-development through shared expertise in oncology and cancer genomic profiling
- Case Study: ITOVEBI (inavolisib), an isoform-specific PI3K inhibitor, received US FDA co-approval with FMI’s FoundationOne Liquid CDx assay after a positive Ph3 readout
